Recursion Pharmaceuticals annual net debt
2021
2022
2023
2024
2025
Recursion Pharmaceuticals Net Debt Growth & History (RXRX)
Recursion Pharmaceuticals's net debt was −$674.4M for fiscal 2025.
View full Recursion Pharmaceuticals company overviewRecursion Pharmaceuticals annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$674.4M | −$180.1M | — |
| 2024 | 2024-12-31 | −$494.3M | −$153.3M | — |
| 2023 | 2023-12-31 | −$340.9M | $158.6M | — |
| 2022 | 2022-12-31 | −$499.5M | −$215.1M | — |
| 2021 | 2021-12-31 | −$284.4M | — | — |
Recursion Pharmaceuticals quarterly net debt
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$488.5M | −$42.7M | — |
| Q1 2026 | 2026-03-31 | −$591.4M | −$175.2M | — |
| Q4 2025 | 2025-12-31 | −$674.4M | −$180.1M | — |
| Q3 2025 | 2025-09-30 | −$586.4M | −$241.1M | — |
| Q2 2025 | 2025-06-30 | −$445.8M | −$53.2M | — |
| Q1 2025 | 2025-03-31 | −$416.1M | −$169.7M | — |
| Q4 2024 | 2024-12-31 | −$494.3M | −$153.3M | — |
| Q3 2024 | 2024-09-30 | −$345.2M | −$7.6M | — |
| Q2 2024 | 2024-06-30 | −$392.6M | −$37.8M | — |
| Q1 2024 | 2024-03-31 | −$246.5M | $175.5M | — |
| Q4 2023 | 2023-12-31 | −$340.9M | $158.6M | — |
| Q3 2023 | 2023-09-30 | −$337.7M | $65.4M | — |
| Q2 2023 | 2023-06-30 | −$354.8M | $46.1M | — |
| Q1 2023 | 2023-03-31 | −$421.9M | $34.6M | — |
| Q4 2022 | 2022-12-31 | −$499.5M | −$215.1M | — |
| Q3 2022 | 2022-09-30 | −$403.1M | −$9.1M | — |
| Q2 2022 | 2022-06-30 | −$400.9M | $219.2M | — |
| Q1 2022 | 2022-03-31 | −$456.5M | −$255.1M | — |
| Q4 2021 | 2021-12-31 | −$284.4M | — | — |
| Q3 2021 | 2021-09-30 | −$394.0M | — | — |
| Q2 2021 | 2021-06-30 | −$620.1M | — | — |
| Q1 2021 | 2021-03-31 | −$201.4M | — | — |
Recursion Pharmaceuticals net debt trends
Between the periods ended 2021-12-31 and 2025-12-31, Recursion Pharmaceuticals's net debt decreased from −$284.4M to −$674.4M, a change of −$390.0M. The latest reported quarter, Q2 2026, shows −$488.5M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Recursion Pharmaceuticals source filings ↗